HELLS: a novel prognostic marker for patients with different subtypes of cervical cancer
Cervical cancer is one of the malignant tumors that threaten the lives of women all over the world. Improving the early diagnosis of cervical cancer is particularly important for the prevention and treatment of cervical cancer. In this study, we used a large sample database to analyze molecules associated with cervical cancer survival and found that HELLS was negatively correlated with cervical cancer prognosis. At the same time, HELLS was highly expressed not only in cervical cancer but also in many other tumor tissues in the pan-cancer analysis. This suggests that HELLS may be a poor prognostic factor in tumors and further stratified analysis found that the effects of HELLS on the prognosis of cervical cancer limited to patients with TP53 mutated or moderated to low grade. As a result, HELLS, as a molecule involved in epigenetic regulation, mTOR signaling, and apoptosis pathway, is an unfavorable factor in the prognosis of cervical cancer patients, and can be used as tumor markers to indicate early diagnosis.
Proceedings of SPIE - The International Society for Optical Engineering
Zhang, Jiaqi, "HELLS: a novel prognostic marker for patients with different subtypes of cervical cancer" (2023). Kean Publications. 375.